Parthenolide

Property	Information
Drug Name	Parthenolide
FDA Approval	No (Used primarily in research settings; not FDA-approved for cancer treatment)
Used for	Investigational use in cancer treatment, specifically for its effects on glioblastoma and glioma stem cells
Clinical Trial Phase	Preclinical studies
Clinical Trial Explanation	Parthenolide is being studied for its potential anti-cancer properties in glioblastoma, particularly focusing on its ability to target and kill glioma stem cells. Research has examined its role in inducing apoptosis and inhibiting the NF-kB pathway, which is crucial for cancer cell survival and proliferation.Property "Has clinical trial explanation" (as page type) with input value "Parthenolide is being studied for its potential anti-cancer properties in glioblastoma, particularly focusing on its ability to target and kill glioma stem cells. Research has examined its role in inducing apoptosis and inhibiting the NF-kB pathway, which is crucial for cancer cell survival and proliferation." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
Common Side Effects	Potential side effects are not well-documented due to its primary use in research; however, as with many natural compounds, potential for gastrointestinal upset exists.
OS without	Not specified
OS with	Not applicable; current research is primarily in preclinical stages focusing on cellular mechanisms
PFS without	Not specified
PFS with	Not applicable; studies are ongoing to determine its effect on disease progression in preclinical models
Usefulness Rating	3
Usefulness Explanation	Parthenolide has shown potential in laboratory studies for its ability to induce apoptosis in cancer cells, particularly glioblastoma stem cells. Its effectiveness in clinical settings remains to be fully established, making its current utility in treatment speculative but promising.Property "Has Usefulness Explanation" (as page type) with input value "Parthenolide has shown potential in laboratory studies for its ability to induce apoptosis in cancer cells, particularly glioblastoma stem cells. Its effectiveness in clinical settings remains to be fully established, making its current utility in treatment speculative but promising." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
Toxicity Level	2
Toxicity Explanation	As a natural compound, parthenolide is generally considered to have low toxicity. However, due to its potent biological activities, it should be used with caution, and further studies are needed to fully understand its safety profile in clinical settings.

Notes: Parthenolide, derived from the feverfew plant, is investigated for its potent anti-inflammatory and anti-cancer properties. Its action against glioma stem cells includes modulation of pathways critical for cell survival and resistance to conventional therapies, offering a novel approach to glioblastoma treatment that warrants further clinical exploration.

This naturally occurring compound from the feverfew plant has garnered interest for its strong anti-inflammatory and potential anti-cancer properties. In glioblastoma research, parthenolide's ability to specifically target cancer stem cells has been a focus, with studies showing its capacity to disrupt crucial survival pathways in these cells. The development of effective delivery mechanisms and formulations to improve bioavailability and therapeutic efficacy in patients remains a significant research area.

Links: * [Preclinical study on Parthenolide's impact in glioblastoma](https://www.ncbi.nlm.nih.gov/pubmed/)

• [Review of Parthenolide's mechanisms of action in cancer therapy](https://www.ncbi.nlm.nih.gov/pmc/articles/)
• [Parthenolide and its potential therapeutic effects on glioblastoma](https://www.sciencedirect.com/science/article/pii/)
• [Parthenolide in cancer prevention and therapy](https://cancerpreventionresearch.aacrjournals.org/)

From Ben Williams Book: Not specified

Loading comments...